Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7251
Source ID: NCT00240253
Associated Drug: Pramlintide Acetate
Title: A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: pramlintide acetate
Outcome Measures: Primary: To evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes., 16 Weeks | Secondary: To evaluate the effects of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes on markers of cardiovascular risk, fasting serum lipids, fasting plasma glucose, waist circumference, and patient-reported outcomes., 16 Weeks
Sponsor/Collaborators: Sponsor: AstraZeneca
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 200
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
Start Date: 2005-10
Completion Date: 2006-06
Results First Posted:
Last Update Posted: 2015-03-31
Locations: Research Site, Phoenix, Arizona, United States|Research Site, Concord, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Gatos, California, United States|Research Site, Salinas, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Denver, Colorado, United States|Research Site, New Britain, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Bloomfield Hills, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Tipton, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Olympia, Washington, United States|Research Site, Spokane, Washington, United States
URL: https://clinicaltrials.gov/show/NCT00240253

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress